The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1550
ISSUE1550
July 2, 2018
Drugs for Inflammatory Bowel Disease
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Inflammatory Bowel Disease
July 2, 2018 (Issue: 1550)
Management of both ulcerative colitis (UC) and Crohn's
disease (CD) is based on disease severity. Disease
location (proctitis, left-sided colitis, or extensive
colitis) also plays a role in drug selection. Some
drugs for induction and maintenance...more
- B Bressler et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterol 2015; 148:1035.
- A Kornbluth et al. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501.
- GR Lichtenstein et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol 2018; 113:481.
- AC Ford et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:601.
- GT Ho et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24:319.
- Budesonide (Uceris) for ulcerative colitis. Med Lett Drugs Ther 2013; 55:23.
- Budesonide rectal foam (Uceris) for ulcerative colitis. Med Lett Drugs Ther 2015; 57:154.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 Sept 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed June 22, 2018.
- A Timmer et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9:CD000478.
- E Prefontaine et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 1:CD000067.
- JF Colombel et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.
- R Panaccione et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146:392.
- AM Abbas et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014; 109:1781.
- M Lemaitre et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017; 318:1679.
- A Vasudevan et al. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. Dig Liv Dis 2018 Feb 10 (epub).
- JW McDonald et al. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2014; 8:CD003459.
- BG Feagan et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014; 146:681.
- I Ordás et al. Long-term efficacy and safety of cyclosporine in a cohort of steroid-refractory acute severe ulcerative colitis patients from the ENEIDA Registry (1989-2013): a nationwide multicenter study. Am J Gastroenterol 2017; 112:1709.
- Golimumab (Simponi) for ulcerative colitis. Med Lett Drugs Ther 2014; 56:25.
- TNF inhibitors for Crohn's disease: when, which, and for how long. Med Lett Drugs Ther 2013; 55:102.
- Inflectra – an infliximab biosimilar. Med Lett Drugs Ther 2017; 59:23.
- JD Feuerstein et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterol 2017; 153:827.
- WJ Sandborn et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146:85.
- S Danese et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160:704.
- M Regueiro et al. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol 2014; 12:1494.
- JF Colombel et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52.
- WJ Sandborn et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829.
- S Schreiber et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239.
- R Panaccione et al. Clinical benefit of long-term adalimumab treatment in patients with Crohn's disease following loss of response or intolerance to infliximab: 96-week efficacy data from GAIN/ADHERE trials. J Crohns Colitis 2018 April 25 (epub).
- WJ Sandborn et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8:688.
- G Van Assche et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61:229.
- X Mariette et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895.
- N Nyboe Andersen et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014; 311:2406.
- GR Lichtenstein et al. Infliximab for Crohn's disease: more than 13 years of real-world experience. Inflamm Bowel Dis 2018; 24:490.
- G D'Haens et al. Lymphoma risk and overall safety profile of adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the Pyramid Registry. Am J Gastroenterol 2018 June 5 (epub).
- Ustekinumab (Stelara) for Crohn's disease. Med Lett Drugs Ther 2017; 59:5.
- B Feagan et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016; 375:1946.
- WJ Sandborn et al. Reduced rates of Crohn's-related surgeries, hospitalizations and alternate biologic initiation with uskekinumab in the IM-UNITI study through 2 years. Gastroenterology 2018; 154:S377. Abstract Sa1743.
- Vedolizumab (Entyvio) for inflammatory bowel disease. Med Lett Drugs Ther 2014; 56:86.
- Natalizumab (Tysabri) for Crohn's disease. Med Lett Drugs Ther 2008; 50:34.
- WJ Sandborn et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711.
- BG Feagan et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699.
- S Schreiber et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol 2018 June 4 (epub).
- D Gevers et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15:382.
- HH Herfarth et al. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2013; 19:1073.
- M Mañosa et al. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis 2013; 19:1889.
- RL Dalal et al. Management of pouchitis and other common complications of the pouch. Inflamm Bowel Dis 2018; 24:989.
- Y Derwa et al. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 46:389.
- S Singh et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2015; 11:CD001176.
- In brief: Risk of pulmonary thromboembolism and death with tofacitinib (Xeljanz). Med Lett Drugs Ther 2019; 61:136.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Inflammatory Bowel Disease
Article code: 1550a
Article code: 1550a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.